Company Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.
Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Oct 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Dr. Lara S. Sullivan M.D., MBA |
Contact Details
Address: 35 Cambridgepark Drive Cambridge, Massachusetts United States | |
| Website | https://www.pyxisoncology.com |
Stock Details
| Ticker Symbol | PYXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782223 |
| CUSIP Number | 747324101 |
| ISIN Number | US7473241013 |
| Employer ID | 83-1160910 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lara S. Sullivan M.D., MBA | Chief Executive Officer, President & Director |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Pamela Yanchik Connealy M.B.A. | Chief Financial Officer & Chief Operating Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio & Program Management |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Ken Kobayashi FACP, M.D. | Chief Medical Officer |
| Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller |
| Stephen T. Worsley MBA | Senior Vice President & Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 16, 2024 | SCHEDULE 13G | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | S-8 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |